Will pharma get hit by Trump's tariffs?

Taking stock of the drug industry, from the lab to the medicine chest

November 21, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mark Schiefelbein/AP STAT+ | The health care industry is girding for Trump's tariffs —and pushing hard for carveouts The health care industry relies heavily on imports, from drugs to everyday hospital supplies, and is looking for ways to minimize or avoid the impact of tariffs. By Tara Bannow and Ed Silverman STAT+ | A documentary about menopause has 'misinformation' and shouldn't be used to educate docs, critics say "State medical boards should not have any documentary making such statements" said Diana Zuckerman of the National Center for Health Research By Ed Silverman STAT+ | Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment Novartis's acquisition gives it a pipeline of gene therapies for three genetic neuromuscular diseases, along with the underlying technology. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser